Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.33 USD
Change Today -0.17 / -1.79%
Volume 37.7K
FOMX On Other Exchanges
Symbol
Exchange
Stuttgart
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

foamix pharmaceuticals ltd (FOMX) Snapshot

Open
$9.43
Previous Close
$9.50
Day High
$9.67
Day Low
$9.27
52 Week High
09/18/14 - $11.00
52 Week Low
10/10/14 - $4.75
Market Cap
200.4M
Average Volume 10 Days
272.3K
EPS TTM
--
Shares Outstanding
21.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FOAMIX PHARMACEUTICALS LTD (FOMX)

Related News

No related news articles were found.

foamix pharmaceuticals ltd (FOMX) Related Businessweek News

No Related Businessweek News Found

foamix pharmaceuticals ltd (FOMX) Details

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for the treatment of acne, impetigo, and other skin conditions in the United States, Germany, and Israel. Its lead product candidates include FMX101, a novel topical foam formulation which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus. The company is also developing FMX103, a version of FMX101 to treat rosacea; and FDX104 to treat chemotherapy-induced rashes, as well as early-stage stable foam formulations of various drugs for the treatment of dermatological indications, including atopic dermatitis, psoriasis, genital warts and actinic keratoses, and herpes and fungal infections. It has development and license agreements with Bayer HealthCare AG, Merz Pharmaceuticals, LLC, and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.

29 Employees
Last Reported Date: 03/17/15
Founded in 2003

foamix pharmaceuticals ltd (FOMX) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $320.3K
President and President of Foamix Pharmaceuti...
Total Annual Compensation: $230.0K
Chairman and Chief Innovation Officer
Total Annual Compensation: $320.1K
Chief Financial Officer
Total Annual Compensation: $141.7K
Executive Vice President of Intellectual Prop...
Total Annual Compensation: $185.8K
Compensation as of Fiscal Year 2014.

foamix pharmaceuticals ltd (FOMX) Key Developments

Foamix Pharmaceuticals Ltd. Announces Consolidated Earnings Results for the Full Year Ended December 31, 2014

Foamix Pharmaceuticals Ltd. announced consolidated earnings results for the full year ended December 31, 2014. For the quarter, the company reported revenues of $5,414,000 against $1,404,000 a year ago. Operating loss was $1,634,000 against $1,356,000 a year ago. Loss for the period was $11,484,000 or $0.79 per basic and diluted share against $2,431,000 or $0.22 per basic and diluted share a year ago. The increase in net loss was primarily due to the increase in non-cash finance expenses on convertible loans and warrants.

Foamix Pharmaceuticals Ltd. to Report Q4, 2014 Results on Mar 18, 2015

Foamix Pharmaceuticals Ltd. announced that they will report Q4, 2014 results at 1:00 PM, GMT Standard Time on Mar 18, 2015

Foamix Pharmaceuticals Ltd., Q4 2014 Earnings Call, Mar 18, 2015

Foamix Pharmaceuticals Ltd., Q4 2014 Earnings Call, Mar 18, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FOMX:US $9.33 USD -0.17

FOMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Heron Therapeutics Inc $14.22 USD +0.23
Johnson & Johnson $100.34 USD +0.20
Sanofi €91.69 EUR +0.31
View Industry Companies
 

Industry Analysis

FOMX

Industry Average

Valuation FOMX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 39.3x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FOAMIX PHARMACEUTICALS LTD, please visit www.foamix.co.il. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.